The Asian Scientist 100
Can Li
Institution
University of Hong Kong
Country
Hong Kong
Field
Engineering
Li is a recipient of the 2023 Croucher Tak Wah Mak Innovation Award for his research exploring the limitations of digital computers in performing tasks accomplished by the human brain, including recognising faces, reasoning based on vague information, and learning from experience.
(Photo: University of Hong Kong)
AWARDS
- 2023 Croucher Tak Wah Mak Innovation Award
Related articles
Artificial Catalysts For Epigenetics Without Enzymes
Scientists in Japan have performed DNA acetylation in living cells using chemical catalysts instead of biological enzymes.
China’s Top Climate Negotiator Wins 2017 LUI Che Woo Prize
Mr Xie Zhenhua received the 2017 LUI Che Woo Sustainability Prize for his critical role during negotiations of the Paris Agreement on climate change.
Tracing The Apple’s Journey Along The Silk Road
By analyzing the genomes of 117 apple varieties, scientists have traced the origin of the domesticated apple and identified key genetic markers for improving apple quality.
Carbon Dots Make Good Fertilizers
Scientists in China have created nanoparticles from rapeseed pollen that increase the yield of lettuce by almost 50 percent.
Visualizing How T-Cells Ready Their Arsenal
Using single-molecule tracking and quantitative analysis, scientists have discovered how T-cells rearrange their surface molecules to mount an immune response.
Perovskite LEDs For A Brighter Future
Using a method known as chemical vapor deposition, scientists in Japan have created perovskite-based LEDs that may one day replace conventional LED lights.
Sorting Cells With Glass Microbubbles
Glass microbeads can be used to count CD4+ T-cells in areas without access to magnetic separators or centrifuges.
Green Cross To Build New Cell Therapy Manufacturing Facility In China
The new Green Cross cell therapy manufacturing facility will be located at the Guian New Area in the Guizhou province.
Takeda Invests US$125 Million In Maverick’s T-Cell Platform
Maverick Therapeutics Inc. and Takeda will collaborate to develop a biologics platform for T-cell immunotherapy over the next five years.